Format

Send to

Choose Destination
Appl Microbiol Biotechnol. 2016 Apr;100(8):3451-61. doi: 10.1007/s00253-016-7388-9. Epub 2016 Mar 3.

Advances in recombinant antibody manufacturing.

Author information

1
Vienna Institute of BioTechnology, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 11, 1190, Vienna, Austria. renate.kunert@boku.ac.at.
2
Vienna Institute of BioTechnology, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 11, 1190, Vienna, Austria.

Abstract

Since the first use of Chinese hamster ovary (CHO) cells for recombinant protein expression, production processes have steadily improved through numerous advances. In this review, we have highlighted several key milestones that have contributed to the success of CHO cells from the beginning of their use for monoclonal antibody (mAb) expression until today. The main factors influencing the yield of a production process are the time to accumulate a desired amount of biomass, the process duration, and the specific productivity. By comparing maximum cell densities and specific growth rates of various expression systems, we have emphasized the limiting parameters of different cellular systems and comprehensively described scientific approaches and techniques to improve host cell lines. Besides the quantitative evaluation of current systems, the quality-determining properties of a host cell line, namely post-translational modifications, were analyzed and compared to naturally occurring polyclonal immunoglobulin fractions from human plasma. In summary, numerous different expression systems for mAbs are available and also under scientific investigation. However, CHO cells are the most frequently investigated cell lines and remain the workhorse for mAb production until today.

KEYWORDS:

Chinese hamster ovary (CHO); Human embryonic kidney (HEK); Mammalian expression systems; Monoclonal antibody (mAb) manufacturing; NS0; Optimization strategies; PER.C6; Process advances

PMID:
26936774
PMCID:
PMC4803805
DOI:
10.1007/s00253-016-7388-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center